dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine

• ChemBase编号: 794
• 分子式: C17H25N3O2S
• 平均质量: 335.4643
• 单一同位素质量: 335.16674806
• SMILES: S(=O)(=O)(N1CCCC1)Cc1cc2c(CCN(C)C)c[nH]c2cc1
• Canonical SMILES: CN(CCc1c[nH]c2c1cc(cc2)CS(=O)(=O)N1CCCC1)C
• InChI: InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
• InChIKey: WKEMJKQOLOHJLZ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine
• IUPAC传统名: almotriptan
• 商标名: Axert; Almogran
• 别名: almotriptan; Almotriptan

登记号

• CAS号: 181183-52-8
• PubChem SID: 160964257; 46505165
• PubChem CID: 123606

理论计算性质

JChem

• Acid pKa: 17.136013
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): -1.8689746
• LogD (pH = 7.4): -0.6067433
• Log P: 1.5233824
• 摩尔折射率: 94.5219 cm^3
• 极化性: 38.129585 Å^3
• 极化表面积: 56.41 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.04
• LOG S: -3.44
• 溶解度: 1.21e-01 g/l

分子性质

理化性质

• 疏水性(logP): 1.6

详细说明

DrugBank - DB00918

• Drug Groups: approved; investigational
• Description: Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks.
• Indication: For the treatment of acute migraine headache in adults
• Pharmacology: Almotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT_1D family) having only a weak affinity for 5-HT_1A, 5-HT_5A, and 5-HT₇ receptors and no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ or 5-HT₄ receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans.
• Affected Organisms: Humans and other mammals
• Half Life: 3-4 hours
• Protein Binding: 35%
• Elimination: Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.
• Distribution: * 180 to 200 L
• Clearance: * 57 L/h [healthy]; * 34.2 L/h [moderate renal impairment (creatinine clearance between 31 and 71 mL/min)]; * 9.8 L/h [severe renal impairment (creatinine clearance between 10 and 30 mL/min)]
• External Links: Wikipedia; RxList; Drugs.com